A Randomized, Open-label, Parallel Group, Multi-center Study to Investigate Pharmacodynamic Effects After Daily Administration of Vilaprisan or Ulipristal Acetate for 8-12 Weeks in Patients With Uterine Fibroids for Whom Hysterectomy is Planned
Phase of Trial: Phase I
Latest Information Update: 31 Aug 2018
At a glance
- Drugs Vilaprisan (Primary) ; Ulipristal
- Indications Uterine leiomyoma
- Focus Biomarker; Pharmacodynamics
- Sponsors Bayer
- 31 Aug 2018 Biomarkers information updated
- 23 Aug 2018 Planned End Date changed from 6 Oct 2019 to 6 Oct 2020.
- 23 Aug 2018 Planned primary completion date changed from 30 Aug 2019 to 30 Aug 2020.